Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Lung Neoplasms 28Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 17Pancreatic Neoplasms 11Glioblastoma 11Melanoma 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 10Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Urinary Bladder Neoplasms 7Neoplasm Metastasis 7Colonic Neoplasms 7Brenner Tumor 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Prostatic Neoplasms 6Mycosis Fungoides 6Leukemia, Lymphocytic, Chronic, B-Cell 6Brain Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

Cisplatin 56Radiotherapy 34Radiotherapy, Intensity-Modulated 28Magnetic Resonance Spectroscopy 24Radiation 20Carboplatin 19pembrolizumab 17Specimen Handling 16Platinum 141,2-diaminocyclohexaneplatinum II citrate 14Paclitaxel 13Cetuximab 13Fluorouracil 10Surgical Procedures, Operative 9Docetaxel 9Biopsy 9Taxes 8Chemoradiotherapy 8Nivolumab 7Fluorodeoxyglucose F18 7Drug Therapy 7durvalumab 6Surveys and Questionnaires 6fludarabine 5X-Rays 5Observation 5Cyclophosphamide 5aldesleukin 4Standard of Care 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Oropharyngeal Neoplasms × Disulfides × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03618134 2023-11-18

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Jonsson Comprehensive Cancer Center

Phase 1/2 Terminated
19 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡